Dr Vincent Forster of Versantis, a Swiss biotech aiming to develop a new generation of liver disease therapeutics and diagnostics, introduces the…

Dr Michael Bauer, a Novartis early development veteran, now serves as CEO of Basel-based Cellestia. Here, Bauer explains why Cellestia’s unique…

Fabian Gerber of SIX Swiss Exchange, Switzerland's principal stock exchange, outlines the importance of life sciences companies to the exchange,…

Josua Jordi of Swiss biotech EraCal explains the company’s technology platform, their work with zebrafish larvae to find a biologic mechanism to…

The SXI Bio & MedTech Index outperformed the Swiss Performance Index (SPI) by 38 percent and NASDAQ Biotech by 46 per cent between 2015 and 2020.…

The top 10 fastest-growing private pharma companies in the UK for 2021, compiled by corporate finance advisory firm Alantra. Featured companies…

The latest UK pharma news, including how new investment in GSK stands to reshape the country’s iconic pharma giant; CDMO Sterling’s latest…

Michael Altorfer, CEO of the Swiss Biotech Association, a membership organisation representing the interests of the Swiss biotech industry, discusses…

In a recent conversation with PharmaBoardroom, Michael Sidler of Redalpine Venture Partners, a venture capital (VC) firm aiming to support founders…

Redalpine Venture Partners' Dr Michael Sidler highlights some of the key trends in the European biotech VC space, the funding and operational…

After an illustrious career in oncology R&D, contributing greatly to the development of cutting-edge cancer therapies at Novartis and Gilead,…

The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical company successfully listed on…